ANXA1 and exocrine pancreatic carcinoma: Nonetheless, a possible novel treatment option for ANXA1 positive, tamoxifen resistant tumors would consist of blocking antibodies, which have already shown efficacy in inhibiting migration and invasion rates in pancreatic carcinoma cells [39].